RT-qPCR Assay Validation Checklist

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-27

Quick Answer

• Validate RT-qPCR assays by confirming primer specificity, amplification efficiency, dynamic range, and reproducibility before experimental data collection begins.
• Follow the MIQE guidelines for reporting essential technical details so other laboratories can interpret and reproduce your results.
• Validation results depend on your specific instrument, reagents, and protocol, so you must verify performance under your own conditions.

At a Glance

Scope of RT-qPCR Assay Validation

RT-qPCR combines reverse transcription of RNA into complementary DNA with quantitative PCR amplification. The method is widely used to measure gene expression, confirm RNA integrity, and detect specific transcripts. Validation is the process of demonstrating that the assay measures the intended target accurately, precisely, and specifically under defined conditions. Without validation, results can be misleading, especially when comparing samples with different RNA quality or when the target is present at low levels.

The validation process covers several distinct components: primer design and specificity, amplification efficiency, dynamic range, limit of detection, reproducibility, and the reverse transcription step itself. Each component requires specific experiments and records. The MIQE guidelines provide a framework for reporting the necessary details so that other laboratories can evaluate the quality of the data. These guidelines emphasize transparency in describing the experimental conditions, controls, and data analysis methods.

Validation is not a one-time event. Reagents change, instruments drift, and new operators join the laboratory. Revalidation is necessary when any of these conditions change. The validation records should be stored in a laboratory notebook or electronic system so that the performance history of the assay is available for review.

Core Principles of RT-qPCR Assay Validation

Primer Design and Specificity

Primer design is the first step in assay validation. Primers should be designed to amplify a single, specific product from the target sequence. The design should avoid regions of high homology with other genes, especially those that are closely related. The primer sequences should be checked against the target genome and against the transcriptome to identify potential off-target binding.

The specificity of the primers is tested experimentally. A single band of the expected size on an agarose gel is the first indication of specificity. A melt curve analysis after the PCR run provides additional confirmation. A single, sharp melt peak indicates that the reaction produced one product. If multiple peaks appear, the primers are likely amplifying multiple products or forming primer dimers.

The amplicon sequence should be confirmed by sequencing at least once during the initial validation. This confirms that the product is the intended target and not a related sequence. The specificity check should be repeated when the assay is used with a new sample type or a new species.

Reverse Transcription Step

The reverse transcription step converts RNA to cDNA. This step is a source of variability in RT-PCR. The efficiency of reverse transcription can vary with the RNA quality, the primer used for the reaction, and the enzyme. The validation should include a control that omits the reverse transcriptase enzyme. This control, called a no reverse transcriptase control, should produce no amplification. If amplification occurs, the signal is likely from genomic DNA contamination.

A second control, the no template control, contains all reaction components except the RNA or cDNA template. This control detects contamination of the reagents or the environment. The no template control should produce no amplification.

The choice of primer for reverse transcription, either oligo-dT, random hexamers, or gene-specific primers, affects the cDNA population. The validation should document which primer is used and the conditions of the reaction. The same reverse transcription conditions should be used for all samples in a study.

Amplification Efficiency

Amplification efficiency is a measure of how well the PCR reaction doubles the target each cycle. The efficiency is calculated from a standard curve. A dilution series of a known template is amplified, and the cycle threshold values are plotted against the log of the template concentration. The slope of the line is used to calculate the efficiency.

An efficiency of 100 percent corresponds to a slope of negative 3.32. Acceptable efficiency is typically between 90 and 110 percent. Efficiency outside this range indicates that the reaction is not optimal. The causes of poor efficiency include inhibitors in the sample, suboptimal primer concentrations, or a template that is not pure.

The efficiency should be measured for each target and for the reference genes. The efficiency of the target and the reference genes should be similar. If the efficiencies differ, the relative quantification is less reliable.

Dynamic Range and Limit of Detection

The dynamic range is the range of template concentrations over which the assay produces a linear response. The dynamic range is determined by the standard curve. The standard curve should include at least 5 to 6 log10-fold dilutions of the template. The linear range is the portion of the curve where the relationship between the log of the concentration and the reaction value is linear.

The limit of detection is the lowest concentration of the template that can be reliably detected. The limit of detection is determined by testing replicate samples at low concentrations. The limit of detection is the concentration at which the target is detected in a defined proportion of the replicates.

The limit of quantification is the lowest concentration at which the target can be quantified with acceptable precision. The limit of quantification is higher than the limit of detection. The validation should report both the limit of detection and the limit of quantification.

Reproducibility

Reproducibility is the degree of agreement between results from different runs, different days, and different operators. The reproducibility is measured by running the same samples in multiple runs and calculating the coefficient of variation. The coefficient of variation should be low, typically below 25 percent for the quantification cycle values.

The reproducibility of the reverse transcription step is also important. The same RNA sample should be reverse transcribed multiple times, and the resulting cDNA should be quantified. The variability from the reverse transcription step is often higher than the variability from the PCR step.

The reproducibility of the assay should be assessed during the initial validation and periodically after that. The assessment should include the same samples and the same conditions.

Reference Gene Selection

Reference genes are used to normalize the expression of the target gene. The reference gene should be expressed at a stable level across the samples being compared. The stability of the reference gene should be verified for each experimental system.

The validation should include the evaluation of multiple reference genes. The stability of the reference genes is assessed by measuring their expression across the samples. The reference gene with the most stable expression is selected for normalization.

The reference gene should be validated under the same conditions as the target gene. The efficiency of the reference gene should be measured, and the specificity should be confirmed.

Workflow for RT-qPCR Assay Validation

Step 1: Define the Assay Purpose

The first step is to define the purpose of the assay. The purpose determines the validation requirements. An assay used for a diagnostic purpose requires more extensive validation than an assay used for a preliminary screening. The purpose also determines the required sensitivity and the acceptable variability.

The assay purpose should be written down. The document should include the target sequence, the intended sample types, and the expected range of target concentrations. The document should also include the intended use of the results.

Step 2: Design and Order Primers

The primers are designed based on the target sequence. The design should follow the standard rules for primer design. The primers should be checked for specificity using a sequence alignment tool. The primers should be ordered from a reliable supplier.

The primers should be resuspended and stored according to the supplier instructions. The stock solution should be stored in a way that prevents degradation. The working solution should be prepared fresh or stored for a short period.

Step 3: Prepare the Standard Template

The standard template is used for the standard curve. The standard template can be a purified PCR product, a plasmid containing the target sequence, or a cDNA sample. The standard template should be quantified accurately. The concentration of the standard template is used to calculate the copy number.

The standard template should be diluted in a series. The dilution series should cover the expected range of the target in the samples. The dilution series should be prepared fresh for each run.

Step 4: Run the Standard Curve

The standard curve is run with the standard template dilutions. The reaction conditions are the same as the conditions for the samples. The standard curve is run in triplicate or more replicates.

The standard curve is used to calculate the efficiency and the dynamic range. The standard curve should be run on the same plate as the samples. The standard curve should be run in the same run as the samples.

Step 5: Test the Specificity

The specificity is tested by running the reaction with the primers and the template. The product is checked on an agarose gel. The product should be a single band of the expected size. The product is also checked by a melt curve.

The product should be sequenced to confirm the identity. The sequencing is done once during the initial validation. The sequencing result should be stored with the validation records.

Step 6: Test the Reproducibility

The reproducibility is tested by running the same samples in multiple runs. The samples are run on different days and by different operators. The coefficient of variation is calculated from the results.

The reproducibility test should include the reverse transcription step. The same RNA sample should be reverse transcribed multiple times. The cDNA should be measured in multiple runs.

Step 7: Evaluate the Reference Genes

The reference genes are evaluated by measuring their expression across the samples. The samples should represent the range of conditions in the experiment. The stability of the reference genes is assessed.

The reference gene with the most stable expression is selected. The selected reference gene is used for normalization.

Step 8: Document the Validation

The validation results are documented. The documentation includes the primer sequences, the reaction conditions, the efficiency, the dynamic range, the limit of detection, and the reproducibility. The documentation also includes the reference gene stability data.

The documentation should be stored in a way that is accessible to the laboratory. The documentation should be updated when the assay is revalidated.

Records and Measurements

What to Record

The validation records should include the following information:

• The primer sequences and the amplicon size
• The reaction conditions, including the reagent concentrations and the thermal cycling protocol
• The standard curve data, including the slope, the efficiency, and the correlation coefficient
• The melt curve data for the specificity check
• The gel image for the specificity check
• The sequencing result for the amplicon
• The limit of detection and the limit of quantification
• The reproducibility data, including the coefficient of variation
• The reference gene stability data
• The date of the validation and the operator

The records should be complete and legible. The records should be stored in a laboratory notebook or in an electronic data system. The records should be available for review.

How to Measure Efficiency

The efficiency is measured from the standard curve. The standard curve is a plot of the reaction value against the log of the template concentration. The slope of the line is used to calculate the efficiency.

The efficiency is calculated using the formula: Efficiency = 10^(-1/slope) - 1. The efficiency is expressed as a percentage. An efficiency of 100 percent corresponds to a slope of -3.4.

The efficiency should be measured for each target and for each reference gene. The efficiency should be measured in the same run as the samples.

How to Measure Reproducibility

The reproducibility is measured by running the same samples in multiple runs. The coefficient of variation is calculated from the values. The coefficient of variation is the standard deviation divided by the mean.

The coefficient of variation should be calculated for the reaction values and for the normalized expression values. The coefficient of variation should be low.

The reproducibility should be measured across runs, days, and operators. The reproducibility should be measured during the initial validation and periodically after that.

Common Failure Patterns

Primer Dimers

Primer dimers are a common problem in RT-PCR. Primer dimers are formed when the primers bind to each other instead of the target. Primer dimers produce a product that is smaller than the target product. The melt curve shows a peak at a lower temperature.

Primer dimers can be reduced by redesigning the primers. The primers should be designed to avoid complementarity between the primers. The primer concentration can be reduced. The annealing temperature can be increased.

Genomic DNA Contamination

Genomic DNA contamination is a common problem in RT-PCR. The contamination can come from the RNA extraction or from the reagents. The contamination produces a signal in the no reverse transcriptase control.

Genomic DNA contamination can be reduced by treating the RNA with DNase. The DNase treatment should be done after the RNA extraction. The DNase should be removed before the reverse transcription.

Efficiency Outside the Acceptable Range

The efficiency outside the acceptable range indicates a problem with the reaction. The efficiency can be too low or too high. The efficiency can be affected by the template, the primers, or the reaction conditions.

The efficiency can be improved by optimizing the reaction conditions. The annealing temperature can be adjusted. The primer concentration can be adjusted. The template concentration can be adjusted.

Poor Reproducibility

Poor reproducibility can be due to the variability in the reverse transcription step, the variability in the PCR step, or the variability in the operator. The reproducibility can be improved by standardizing the protocol and by using the same operator for the entire experiment.

The reproducibility can be improved by using a master mix for the PCR. The master mix reduces the variability in the pipetting. The reproducibility can be improved by using the same batch of reagents for the entire experiment.

Safety and Regulatory Context

Biosafety Considerations

RT-PCR involves the handling of RNA and cDNA. The RNA is often extracted from biological samples. The samples can contain infectious agents. The laboratory should follow the biosafety guidelines for the handling of the samples.

The biosafety level of the laboratory should be appropriate for the samples. The laboratory should have the appropriate containment equipment. The laboratory should have the appropriate personal protective equipment.

The biosafety guidelines are described in the Biosafety in Microbiological and Biomedical Laboratories manual. The manual provides the principles of biosafety and the containment levels. The manual is published by the CDC and the NIH.

Recombinant and Synthetic Nucleic Acid Oversight

The use of recombinant or synthetic nucleic acid molecules is subject to the NIH Guidelines. The guidelines apply to the use of the molecules in the laboratory. The guidelines require the institutional oversight of the work.

The laboratory should be aware of the requirements of the NIH guidelines. The laboratory should have the appropriate approvals for the work. The laboratory should follow the guidelines for the handling and the disposal of the materials.

Quality and Calibration

The quality of the RT-PCR assay depends on the quality of the reagents and the equipment. The pipettes should be calibrated regularly. The thermal cycler should be calibrated regularly. The reagents should be stored according to the instructions.

The quality of the assay should be monitored by the use of the controls. The controls should be included in each run. The controls should be checked for the expected results.

The measurement science is supported by the National Institute of Standards and Technology. The NIST provides the standards and the calibration services for the laboratory. The NIST also provides the reference materials for the quality control.

Limitations and Professional Escalation

Limitations of the Validation

The validation of the RT-PCR assay is limited to the conditions under which the validation was performed. The validation does not guarantee the performance of the assay under different conditions. The validation should be repeated when the conditions change.

The validation is limited by the quality of the standard template. The standard template should be quantified accurately. The standard template should be stable.

The validation is limited by the quality of the RNA. The RNA should be of high quality. The RNA should be free of contaminants.

When to Escalate

The laboratory should escalate the issue to the supervisor when the validation fails. The escalation should include the data and the description of the problem. The escalation should be done in a timely manner.

The laboratory should escalate the issue when the efficiency is outside the acceptable range. The laboratory should escalate the issue when the reproducibility is poor. The laboratory should escalate the issue when the specificity is not confirmed.

The laboratory should escalate the issue when the problem cannot be resolved by the troubleshooting. The escalation should be done to the supervisor or the laboratory manager.

Decision Framework for Assay Acceptance and Rejection

Validation generates data, but data alone does not tell you whether to proceed with an assay. You need a structured decision framework that converts validation measurements into clear accept, reject, or conditional-accept outcomes. This framework prevents two common errors: accepting an assay with marginal performance because you have already invested time in it, and rejecting an assay that could be salvaged with a targeted optimization step.

Define Acceptance Criteria Before Data Collection

Write the acceptance criteria before you run the first validation plate. This step is often skipped, and the consequence is that criteria drift to match whatever data you happen to obtain. The criteria should be specific, measurable, and tied to the intended use of the assay.

For a gene expression study comparing two treatment groups, the criteria might include efficiency between 90 and 110 percent, a dynamic range spanning at least 5 log10 dilutions, and a coefficient of variation below 25 percent for replicate quantification cycle values. For a diagnostic application or a clinical trial endpoint, the criteria should be stricter. The MIQE guidelines emphasize that the level of validation should be proportionate to the intended application, and you should document the rationale for your chosen thresholds.

Record the acceptance criteria in the validation plan. The plan should include the target sequence, the sample types, the expected concentration range, and the specific thresholds for each validation component. When the validation data are collected, compare each result against the prewritten criteria. Do not adjust the criteria after seeing the data unless you document the reason for the change and the potential impact on data interpretation.

Categorize Validation Outcomes

Use a three-tier outcome system for each validation component. Tier one is pass, meaning the measurement meets the acceptance criteria. Tier two is conditional, meaning the measurement falls outside the criteria but the deviation is small and the cause is understood. Tier three is fail, meaning the measurement is outside the criteria and the cause is not resolved.

For efficiency, a pass is 90 to 110 percent. A conditional outcome is 85 to 89 percent or 111 to 115 percent with a documented cause such as a slightly impure standard template. A fail is below 85 percent or above 115 percent, or any value outside the range with no identified cause. For specificity, a pass is a single melt peak and a single band of the expected size. A conditional is a single melt peak with a faint secondary band that sequencing confirms is a nontarget product. A fail is multiple melt peaks or a band of the wrong size.

For reproducibility, a pass is a coefficient of variation below 25 percent for the quantification cycle values. A conditional is 25 to 30 percent with the variability traced to a specific pipetting step. A fail is above 30 percent or variability that cannot be traced to a specific cause.

The tier system forces you to make an explicit decision about each component. An assay with any fail component should not be used for data collection. An assay with conditional components can be used only if you document the condition, the cause, and the potential impact on the results.

Apply the Decision Rules

The overall assay decision is based on the combination of the component decisions. The rules are as follows.

If all components are a pass, the assay is accepted for the defined purpose and the defined conditions. Record the acceptance date and the operator.

If any component is a fail, the assay is rejected. Do not use the assay for data collection until the failed component is resolved and the validation is repeated. The rejection should be recorded with the reason and the date.

If one or more components are conditional, the assay is accepted with conditions. The conditions must be documented in the validation record. The conditions might include a requirement to run a no reverse transcriptase control on every plate, a requirement to use a specific batch of primers, or a requirement to include a standard curve on every plate. The conditional acceptance should be reviewed by a second person, such as a laboratory manager or a senior researcher.

The decision rules should be applied consistently. If you accept a conditional assay for one experiment, you must apply the same rule to the next experiment. The decision framework is only useful if it is applied without exception.

Revalidation Triggers

The decision framework also defines when revalidation is required. Revalidation is not the same as a full initial validation. Revalidation is a targeted set of measurements that confirm the assay still performs within the acceptance criteria after a change.

The triggers for revalidation are a new primer batch, a new reverse transcriptase enzyme batch, a new master mix batch, a new instrument, a new operator, or a change in the sample type. The extent of the revalidation depends on the change. A new primer batch requires a full specificity check and an efficiency measurement. A new operator requires a reproducibility check. A new instrument requires a full standard curve and a reproducibility check.

The revalidation results are compared to the original acceptance criteria. If the revalidation measurements fall within the criteria, the assay remains accepted. If the measurements fall outside the criteria, the assay is placed on hold until the cause is identified and resolved.

The revalidation records are stored with the original validation records. The record should include the date of the change, the nature of the change, the measurements, and the decision.

Record System for Validation Data

The validation records are the evidence that the assay is reliable. A disorganized record system undermines the validation even if the measurements are correct. The record system should be designed so that a reviewer can trace the history of the assay from the initial design to the most recent revalidation.

Structure the Validation File

Create a separate validation file for each assay. The file should be named with the target gene and the assay identifier. The file should contain the following sections.

The first section is the assay design. This section contains the target sequence, the primer sequences, the amplicon size, the reverse transcription primer type, and the intended sample types. The design section also contains the in silico specificity check results.

The second section is the initial validation. This contains the standard curve data, the efficiency calculation, the melt curve data, the gel image, the sequencing result, the limit of detection, the limit of quantification, and the reproducibility data. Each entry should have a date and the operator name.

The third section is the revalidation history. This contains the records of each revalidation event. Each entry should have the date, the reason for the revalidation, the measurements, and the decision.

The fourth section is the acceptance criteria. This contains the written criteria for each validation component and the date the criteria were established.

The fifth section is the decision log. This contains the pass, conditional, or fail decision for each validation component and the overall assay decision.

Use a Template for Each Validation Run

A standardized template reduces the chance of missing a required measurement. The template should have fields for the date, the operator, the instrument, the reagent lot numbers, the primer lot numbers, the standard template concentration, the dilution series, the reaction values, the calculated efficiency, the melt curve interpretation, the gel interpretation, and the decision.

The template should be filled out at the time of the experiment. Do not rely on memory to reconstruct the details later. The template should be stored in the assay file.

The template also serves as a checklist. If a field is empty, the validation is incomplete. The empty field should be addressed before the assay is accepted.

Record the Raw Data

The raw data are the quantification cycle values for each well, the standard curve values, and the melt curve data. The raw data should be stored in a format that can be reopened and reanalyzed. The analysis software output should be saved with the raw data.

The raw data are the primary evidence. The calculated values, such as the efficiency and the coefficient of variation, are derived from the raw data. If a reviewer questions the calculated values, the raw data must be available for reanalysis.

The raw data should be stored in the assay file or in an electronic data system with a link to the assay file. The storage location should be documented in the validation record.

Record the Decisions

The decision log is the record of the accept, reject, or conditional decisions. Each decision should include the date, the operator, the component, the measured value, the acceptance criterion, and the decision. The decision log should be reviewed periodically to confirm that the assay is still within the acceptance criteria.

The decision log is also the record of the assay history. If the assay is used for a long period, the decision log shows the performance over time. The log can be used to identify trends, such as a gradual decrease in efficiency that indicates a reagent problem.

Troubleshooting Method for Failed Validation

When a validation component fails, the troubleshooting should be systematic. The goal is to identify the cause of the failure and to correct it. The troubleshooting method is a sequence of steps that isolates the variable.

Step 1: Confirm the Failure

The first step is to confirm that the failure is real. A single failed measurement can be due to a pipetting error or a transient instrument issue. Repeat the measurement. If the failure is reproduced, the failure is real. If the failure is not reproduced, the failure was likely due to a random error.

The confirmation step should be documented. The repeat measurement should be recorded with the same detail as the original measurement.

Step 2: Isolate the Variable

The next step is to isolate the variable. The failure can be due to the template, the primers, the reagents, the instrument, or the operator. The isolation is done by changing one variable at a time.

For an efficiency failure, the first variable to check is the standard template. The template concentration should be verified by an independent method. The template should be checked for degradation. The template should be checked for inhibitors.

If the template is not the cause, the next variable is the primer concentration. The primer concentration can be tested by running a gradient of primer concentrations. The optimal primer concentration is the one that produces the highest efficiency and the lowest quantification cycle value.

If the primer concentration is not the cause, the next variable is the annealing temperature. The annealing temperature can be tested by running a temperature gradient. The optimal annealing temperature is the one that produces a single melt peak and the highest efficiency.

Step 3: Test the Corrected Condition

Once the variable is identified, the corrected condition is tested. The test is a full validation run for the affected component. The corrected condition is tested with the same template and the same protocol as the original validation.

The corrected condition is accepted if the measurement meets the acceptance criteria. The corrected condition is recorded in the validation file. The original failed measurement is also recorded.

Step 4: Escalate if the Failure Persists

If the failure persists after the systematic troubleshooting, the issue should be escalated. The escalation is to the supervisor or the laboratory manager. The escalation should include the validation data, the troubleshooting steps, and the results of each step.

The escalation is not a failure of the operator. The escalation is a recognition that the problem is beyond the scope of the troubleshooting method. The supervisor may have access to additional resources, such as a different instrument or a different reagent batch.

The escalation should be documented in the validation file. The documentation should include the date of the escalation, the person to whom the issue was escalated, and the outcome.

Comparison of Validation Approaches

The validation approach can be adapted to the purpose of the assay. The comparison below shows the differences between a research assay and a regulated assay.

The research assay is appropriate for hypothesis-driven experiments where the goal is to compare relative expression between samples. The full assay is appropriate for diagnostic or clinical applications where the results are used for patient care decisions. The NIST Laboratory Programs provide the measurement science context for the calibration and the quality control that support the full assay.

The choice of the approach should be documented in the validation plan. The plan should state the purpose of the assay and the level of validation required. The plan should be reviewed by the supervisor before the validation begins.

Practical Implementation Steps

The decision framework and the record system are implemented in the laboratory. The implementation steps are as follows.

Step 1: Write the Validation Plan

The validation plan is the written document that defines the purpose, the acceptance criteria, and the validation experiments. The plan is written before the validation begins. The plan is reviewed by the supervisor.

Step 2: Create the Validation File

The validation file is created for the assay. The file contains the sections described above. The file is stored in the laboratory notebook or the electronic data system.

Step 3: Run the Validation Experiments

The validation experiments are run according to the plan. The data are recorded in the template. The raw data are stored.

Step 4: Apply the Decision Framework

The data are compared to the acceptance criteria. The decision is recorded in the decision log. The assay is accepted, rejected, or accepted with conditions.

Step 5: Store the Records

The validation file is stored. The file is accessible to the laboratory. The file is updated when the assay is revalidated.

Step 6: Review the Validation Periodically

The validation is reviewed periodically. The review includes the decision log and the revalidation history. The review is performed by the supervisor.

The implementation is complete when the validation file is complete and the decision is recorded. The assay is then ready for use in the defined purpose and the defined conditions.

Common Failure Patterns in the Decision Framework

The Assay Is Accepted Without a Decision

The most common failure is that the validation data are collected but no decision is recorded. The assay is used for data collection without a formal acceptance. This failure is prevented by the decision log. The decision log is the record that the assay was accepted.

The Acceptance Criteria Are Adjusted After the Data

The second common failure is that the acceptance criteria are adjusted after the data are collected. The adjustment is made to make the assay pass. This failure is prevented by writing the criteria before the data collection. The criteria are the standard against which the data are compared.

The Revalidation Is Not Performed

The third common failure is that the revalidation is not performed when the conditions change. The assay is used with a new primer batch or a new instrument without a revalidation. This failure is prevented by the revalidation triggers. The triggers are written in the validation plan.

The Records Are Incomplete

The fourth common failure is that the records are incomplete. The raw data are not stored, or the decision is not recorded. This failure is prevented by the template. The template requires the data to be recorded at the time of the experiment.

Professional Escalation Criteria

The escalation criteria are the conditions under which the operator should involve the supervisor. The escalation is a professional step that ensures the problem is resolved.

The operator should escalate when the validation fails and the cause is not identified after the systematic troubleshooting. The operator should escalate when the failure is reproduced and the corrected solution does not resolve the failure. The operator should escalate when the failure is in a component that is critical to the assay, such as the specificity or the efficiency.

The escalation should include the data, the troubleshooting steps, and the results. The escalation should be documented in the validation file. The supervisor should respond in a timely manner.

The escalation is not a sign of failure. The escalation is a sign that the operator is following the validation framework. The framework is designed to identify the problems and to resolve them in a systematic way.

Frequently Asked Questions

What is the difference between RT-PCR and qPCR?

RT-PCR refers to the reverse transcription step that converts RNA to cDNA. qPCR refers to the quantitative PCR step that measures the amount of the target. RT-qPCR combines the two steps. The reverse transcription step is the first step, and the quantitative PCR step is the second step.

How do I calculate the efficiency of my RT-qPCR assay?

The efficiency is calculated from the standard curve. The standard curve is a plot of the reaction value against the log of the template concentration. The slope of the line is used to calculate the efficiency. The efficiency is calculated using the formula: Efficiency = 10^(-1/slope) - 1. The efficiency is expressed as a percentage.

What is the difference between the limit of detection and the limit of quantification?

The limit of detection is the lowest concentration of the target that can be reliably detected. The limit of quantification is the lowest concentration at which the target can be quantified with a defined precision. The limit of quantification is higher than the limit of detection.

How many reference genes should I use for normalization?

The number of reference genes depends on the stability of the reference genes. The reference genes should be evaluated across the samples. The reference gene with the most stable expression is selected. The use of multiple reference genes can improve the reliability of the normalization.

What is the no reverse transcriptase control?

The no reverse transcriptase control is a control that omits the reverse transcriptase enzyme. The control is used to detect the genomic DNA contamination. The control should produce no signal. If the control produces a signal, the RNA is contaminated with genomic DNA.

How often should I revalidate my RT-qPCR assay?

The assay should be revalidated when the conditions change. The conditions include the reagent batch, the primer batch, the instrument, and the operator. The assay should be revalidated when the performance of the assay is in question.

What is the MIQE guidelines?

The MIQE guidelines are the Minimum Information for Publication of Quantitative Real-Time PCR Experiments. The guidelines provide the list of the information that should be reported for the qPCR experiments. The guidelines are intended to improve the transparency and the reproducibility of the qPCR experiments.

What is the role of the reference gene in RT-qPCR?

The reference gene is used to normalize the expression of the target gene. The reference gene should be stable across the samples. The reference gene is used to correct for the differences in the amount of the RNA and the efficiency of the reverse transcription.

qPCR Copy Number Calculator

Use this calculation as a check on recorded inputs and method-specific assumptions. It does not replace assay validation, quality controls, or professional interpretation.

Related Molecular Biology Guides

• PCR Types and Their Applications: A Comprehensive Guide
• Knockout Mouse: A Comprehensive Guide to Gene Function Studies
• qPCR Melt Curve Interpretation: A Practical Guide
• How to Read Melt Curve qPCR: A Beginner's Guide
• PCR Reaction: Principles, Steps, and Applications

References and Further Reading

• Molecular Biology and Laboratory Methods. National Library of Medicine.
• Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
• NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules. National Institutes of Health.
• Addgene Protocols. Addgene.
• MIQE Guidelines. Clinical Chemistry.
• NIST Laboratory Programs. National Institute of Standards and Technology.
• Expression of miR-195-5p in the serum of children with autism spectrum disorder and its correlation with the severity of the disease.. Psychiatric genetics, 2025.
• RPS29 as a potential early diagnostic biomarker for necrotizing enterocolitis: validation from transcriptomic and proteomic cohorts.. 2026.
• Exploration of the expression and regulatory mechanisms of platelet miR-223-3p in hand, foot, and mouth disease (HFMD) complicated by encephalitis.. 2026.
• Design, development, and validation of a strand-specific RT-qPCR assay to differentiate replicating versus nonreplicating Rabies virus.. Journal of Virological Methods, 2024.
• Development and Validation of a Triplex RT-qPCR Assay for Rapid Clinical Diagnosis and Serotyping of Feline Infectious Peritonitis Virus. International Journal of Molecular Sciences, 2026.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.